Is Alpelisib Plus Fulvestrant Cost-Effective for Treating PIK3CA-Mutation, HR+/HER2- Advanced Breast Cancer in the USA?

Wenhua WuHuiting LinJiaqin CaiHong SunJia LiuCongting HuXiaoXia Wei

Published in: Clinical drug investigation (2023)

At current drug prices, alpelisib plus fulvestrant is not cost effective for patients with PIK3CA-mutated, HR+/HER2- ABC from a US payer perspective. Given the considerable progression-free survival (PFS) and overall survival (OS) benefits observed with alpelisib in this setting, further discussion and negotiation of the price of alpelisib are warranted to provide more favorable economic outcomes and thereby increase the value of the alpelisib plus fulvestrant regimen in patients.

Keyphrases

free survival
metastatic breast cancer
end stage renal disease
ejection fraction
newly diagnosed
chronic kidney disease
prognostic factors
type diabetes
emergency department
protein kinase
patient reported outcomes
drug induced